Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

8 de maio de 2018 atualizado por: Vertex Pharmaceuticals Incorporated

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)

Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene and with a second CFTR mutation that is not likely to respond to VX-661 and/or IVA therapy (F508del/not responsive [NR]).

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

168

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Austrália
      • Chermside, Austrália
      • Herston, Austrália
      • Innsbruck, Austrália
      • Westmead, Austrália
    • Queensland
      • Brisban, Queensland, Austrália
  • Canadá
      • Montreal, Canadá
    • British Columbia
      • Vancouver, British Columbia, Canadá
  • Espanha
      • Barcelona, Espanha
      • Valencia, Espanha
  • Estados Unidos
    • Alabama
      • Birmingham, Alabama, Estados Unidos
    • California
      • La Jolla, California, Estados Unidos
      • Los Angeles, California, Estados Unidos
    • Colorado
      • Denver, Colorado, Estados Unidos
    • Florida
      • Miami, Florida, Estados Unidos
    • Georgia
      • Atlanta, Georgia, Estados Unidos
    • Illinois
      • Chicago, Illinois, Estados Unidos
    • Indiana
      • Indianapolis, Indiana, Estados Unidos
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos
      • Detroit, Michigan, Estados Unidos
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos
    • Missouri
      • Kansas City, Missouri, Estados Unidos
    • Nebraska
      • Omaha, Nebraska, Estados Unidos
    • New York
      • New York, New York, Estados Unidos
    • Ohio
      • Cincinnati, Ohio, Estados Unidos
    • Tennessee
      • Memphis, Tennessee, Estados Unidos
    • Texas
      • Austin, Texas, Estados Unidos
      • Dallas, Texas, Estados Unidos
    • Virginia
      • Richmond, Virginia, Estados Unidos
    • Washington
      • Seattle, Washington, Estados Unidos
      • Spokane, Washington, Estados Unidos
  • França
      • Bron Cedex, França
      • Montpellier Cedex 5, França
      • Paris, França
      • Paris Cedex 14, França
      • Paris Cedex 19, França
  • Israel
      • Haifa, Israel
      • Hashomer, Israel
      • Jerusalem, Israel
      • Petah Tikva, Israel
  • Áustria
      • Graz, Áustria
      • Innsbruck, Áustria
      • Salzburg, Áustria

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Confirmed diagnosis of CF defined as a sweat chloride value greater than or equal to (>=)60 millimole per liter (mmol/L) by quantitative pilocarpine iontophoresis.
  • Heterozygous for the F508del-CFTR mutation and with a second CFTR mutation that is not likely to respond to VX-661 and/or ivacaftor therapy, genotype to be confirmed via assessment at the Screening Visit.
  • Forced Expiratory Volume in 1 Second (FEV1) >=40 percent (%) and less than or equal to (<=)90% of predicted normal for age, sex, and height at Screening Visit.

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug).
  • History of solid organ or hematological transplantation.
  • Ongoing or prior participation in an investigational drug study or use of commercially available CFTR modulator within 30 days of screening.
  • Pregnant or nursing females.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: VX-661/IVA
VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
Medicamento: Ivacaftor
Outros nomes:
  • VX-770
  • IVA
Medicamento: VX-661 plus ivacaftor combination
Comparador de Placebo: Placebo
Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
Medicamento: Placebo (matched to VX-661 plus ivacaftor combination)
Medicamento: Placebo (matched to ivacaftor)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12
Prazo: Baseline, Through Week 12
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
Baseline, Through Week 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12
Prazo: Baseline, Through Week 12
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Baseline, Through Week 12
Number of Pulmonary Exacerbation Events
Prazo: Baseline through Week 12
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.
Baseline through Week 12
Number of Pulmonary Exacerbation Events Per Year
Prazo: Baseline through Week 12
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Total number of days on study is equal to the Week 12 date or the last dose date (whichever occurs last) minus first dose date plus 1. The total number of years (48 weeks) on study is equal to the total number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.
Baseline through Week 12
Absolute Change From Baseline in Body Mass Index (BMI) at Week 12
Prazo: Baseline, Week 12
BMI was defined as weight in kilogram (kg) divided by height*height in square meter (m^2).
Baseline, Week 12
Relative Change From Baseline in Percent Predicted FEV1 Through Week 12
Prazo: Baseline, Through Week 12
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
Baseline, Through Week 12
Absolute Change From Baseline in Sweat Chloride Through Week 12
Prazo: Baseline, Through Week 12
Sweat samples were collected using an approved collection device.
Baseline, Through Week 12
Number of Participants With at Least One Pulmonary Exacerbation Through Week 12
Prazo: Baseline through Week 12
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
Baseline through Week 12
Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)
Prazo: Baseline, Week 12
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from infinity to +infinity; where 0: same mean, >0: a greater mean, and <0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age Z-score (BMI z-score). BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the paediatric population.
Baseline, Week 12
Absolute Change From Baseline in Body Weight at Week 12
Prazo: Baseline, Week 12
Baseline, Week 12
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: Baseline up to Week 16
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 16 was considered treatment-emergent.
Baseline up to Week 16
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolite (M1 VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
Prazo: Pre-morning dose on Week 2, Week 4, Week 8 and Week 12
This outcome was not planned to be assessed in Placebo arm.
Pre-morning dose on Week 2, Week 4, Week 8 and Week 12

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Vertex Pharmaceuticals Incorporated

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de agosto de 2015

Conclusão Primária (Real)

7 de junho de 2016

Conclusão do estudo (Real)

7 de junho de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

28 de julho de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de agosto de 2015

Primeira postagem (Estimativa)

5 de agosto de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de junho de 2018

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de maio de 2018

Última verificação

1 de maio de 2018

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • VX14-661-107
  • 2014-004787-37 (Número EudraCT)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever